Sophiris Bio Announces Complete Enrollment in Phase 2b Topsalysin Study of Localized Prostate Cancer
(World News USA)

SAN DIEGO and VANCOUVER, British Columbia, Dec. 11, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the `Company` or `Sophiris`) today announced that it has completed enrollment in its Phase 2b study to evaluate the safety and tolerability of topsalysin in treating men with clinically significant localized prostate cancer. Topsalysin (PRX302) is an innovative, first-in-class transmembrane pore-forming protein genetically modified to be activated only in the presence of enzymatically-active PSA, which is only found within the prostate. `I am delighted that Sophiris has completed enrollment into its multi-center Phase 2b study. My thanks to the men and my colleagues in each clinical...